IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0136731.html
   My bibliography  Save this article

The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer

Author

Listed:
  • Stefania Gori
  • Alessandro Inno
  • Elena Fiorio
  • Jennifer Foglietta
  • Antonella Ferro
  • Marcella Gulisano
  • Graziella Pinotti
  • Marta Gubiotti
  • Maria Giovanna Cavazzini
  • Monica Turazza
  • Simona Duranti
  • Valeria De Simone
  • Laura Iezzi
  • Giancarlo Bisagni
  • Simon Spazzapan
  • Luigi Cavanna
  • Chiara Saggia
  • Emilio Bria
  • Elisabetta Cretella
  • Patrizia Vici
  • Daniele Santini
  • Alessandra Fabi
  • Ornella Garrone
  • Antonio Frassoldati
  • Laura Amaducci
  • Silvana Saracchini
  • Lucia Evangelisti
  • Sandro Barni
  • Teresa Gamucci
  • Lucia Mentuccia
  • Lucio Laudadio
  • Alessandra Zoboli
  • Fabiana Marchetti
  • Giuseppe Bogina
  • Gianluigi Lunardi
  • Luca Boni

Abstract

Background: The management of pT1a-b pN0 HER2-positive breast cancer is controversial and no data about the efficacy of trastuzumab in this setting are available from randomized clinical trials. The aims of this retrospective study were to assess how patients are managed in clinical practice in Italy, which clinical or biological characteristics influenced the choice of adjuvant systemic therapy and the outcome of patients. Methods: Data of consecutive patients who underwent surgery from January 2007 to December 2012 for HER2-positive, pT1a-b pN0 M0 breast cancer were retrospectively collected from 28 Italian centres. Analysis of contingency tables and multivariate generalized logit models were used to investigate the association between the baseline clinical and biological features and the treatment strategy adopted. Results: Among 303 enrolled patients, 204 received adjuvant systemic therapy with trastuzumab, 65 adjuvant systemic therapy without trastuzumab and 34 did not receive adjuvant systemic therapy. At the multivariate analysis age, tumor size, proliferation index and hormone receptor status were significantly associated with the treatment choice. Five-year disease-free survival (DFS) probability was 95%, 94.3% and 69.6% for patients treated with adjuvant systemic therapy and trastuzumab, with adjuvant systemic therapy without trastuzumab and for patients who did not receive adjuvant systemic therapy, respectively (p

Suggested Citation

  • Stefania Gori & Alessandro Inno & Elena Fiorio & Jennifer Foglietta & Antonella Ferro & Marcella Gulisano & Graziella Pinotti & Marta Gubiotti & Maria Giovanna Cavazzini & Monica Turazza & Simona Dura, 2015. "The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer," PLOS ONE, Public Library of Science, vol. 10(9), pages 1-14, September.
    • Handle: RePEc:plo:pone00:0136731
    DOI: 10.1371/journal.pone.0136731
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0136731
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0136731&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0136731?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Qiong Zhou & Wenjin Yin & Yueyao Du & Jinsong Lu, 2014. "For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-7, January.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      More about this item

      Statistics

      Access and download statistics

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0136731. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.